At a glance
ClinicalIndex Comparison RecordN/AActive· 180 enrolled
Drug / intervention
Aspirin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk
In Brief
A clinical study evaluating Aspirin and Placebo for Aspirin for Colorectal Cancer. Active but no longer recruiting, targeting 180 participants across 1 site.
Detailed Summary
This research study is investigating the use of aspirin as a potential chemopreventive agent to reduce risk of colorectal cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/AActive
201520162017201820192020202120222023202420252026202720282029
First PostedMar 2015
Enrollment StartJul 2015
Primary CompletionApr 2019
TodayJul 2026
Study CompletionJul 2029
First PostedMar 20, 2015
Enrollment StartJul 6, 2015
Primary CompletionApr 11, 2019
Study CompletionJul 1, 2029
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 11.3 years ago
Interventions
Aspirindrug
Placebo for Aspirindrug